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Abstract
Background: Spontaneous preterm birth (SPB, before 37 gestational weeks) is a major cause of perinatal mortality and
morbidity, but its pathogenesis remains unclear. Studies on SPB have been hampered by the limited availability of markers
for SPB in predelivery clinical samples that can be easily compared with gestational age-matched normal controls. We
hypothesize that SPB involves aberrant placental RNA expression, and that such RNA transcripts can be detected in
predelivery maternal plasma samples, which can be compared with gestational age-matched controls.
Principal Findings: Using gene expression microarray to profile essentially all human genes, we observed that 426 probe
signals were changed by .2.9-fold in the SPB placentas, compared with the spontaneous term birth (STB) placentas.
Among the genes represented by those probes, we observed an over-representation of functions in RNA stabilization,
extracellular matrix binding, and acute inflammatory response. Using RT-quantitative PCR, we observed differences in the
RNA concentrations of certain genes only between the SPB and STB placentas, but not between the STB and term elective
cesarean delivery placentas. Notably, 36 RNA transcripts were observed at placental microarray signals higher than a
threshold, which indicated the possibility of their detection in maternal plasma. Among them, the IL1RL1 mRNA was tested
in plasma samples taken from 37 women. It was detected in 6 of 10 (60%) plasma samples collected during the presentation
of preterm labor (#32.9 weeks) in women eventually giving SPB, but was detected in only 1 of 27 (4%) samples collected
during matched gestational weeks from women with no preterm labor (Fisher exact test, p=0.00056).
Conclusion: We have identified 36 SPB-associated RNA transcripts, which are possibly detectable in maternal plasma. We
have illustrated that the IL1RL1 mRNA was more frequently detected in predelivery maternal plasma samples collected from
women resulting in SPB than the gestational-age matched controls.
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Introduction
In developed countries, reported rates of preterm birth or
deliverybefore37completedweeks ofgestation, aregenerally5–9%
[1]. Of all preterm births, around 65% are spontaneous preterm
births (SPB; resulting from spontaneous preterm labor and preterm
pre-labor rupture of membranes), while the remaining are indicated
preterm births delivered for medical reasons [2].
Genetic studies have reported associations of certain polymor-
phisms in individual genes involved in infection and inflammation
with preterm birth [3–13]. Recently, a genome-wide linkage
analysis performed in the Finnish families with recurrent SPB has
revealed insulin-like growth factor 1 receptor (IGF1R) as a SPB
susceptibility gene [14]. Replication of these association and
linkage studies in larger cohorts and across populations is pending.
To shed light on the mechanism of SPB and search for markers
to predict SPB, investigators have performed proteomic studies to
identify the proteins that are differentially present in bodily fluids
of pregnant women eventually giving SPB [15,16], or having intra-
amniotic infection, which is commonly associated with SPB
[17,18]. A study on the reproducibility of certain maternal serum
peptides to correctly classify SPB has been planned using an
independent cohort [15].
To the best of our knowledge, transcriptomic studies directly
comparing the genome-wide gene expression profiles between the
SPB placentas and the spontaneous term birth (STB) placentas
have not yet been published. Published placental gene expression
studies were often confounded by the different modes of delivery
or underlying obstetric complications besides SPB [19,20]. Thus,
the expression profile of gene associated with SPB was not
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gene expression profiles in the placentas delivered by spontaneous
births only, i.e. SPB and STB, but not indicated preterm births nor
pregnancies with other obstetric complications. We have profiled
the RNA levels of essentially all human genes in the SPB and STB
placentas, using a gene expression microarray platform.
Previously, we and others have observed that the placenta
releases its nucleic acids in maternal plasma [21,22]. Based on the
systematically profiling of gene expression in the placenta, we have
discovered a panel of unreported pregnancy-associated RNA
transcripts and microRNAs in maternal plasma, [23,24]. Thus, in
this study, we have also tested if the SPB-associated RNA
transcripts, as identified systematically in the placenta using
microarray, are detectable in maternal plasma. This may result in
novel markers for SPB in maternal plasma.
Materials and Methods
Objectives
To investigate if SPB involves any aberrant gene expression in
the placenta, we profiled the RNA expression levels of all human
genes by microarray in the placentas collected from SPB, and
compared with the data from STB. To decipher if certain genes
were associated in (a) the pathogenesis of SPB, and/or (b) the
normal term spontaneous labor process, we compared the reverse-
transcriptase quantitative polymerase chain reaction (RT-qPCR)
data on the placentas from (a) SPB versus STB, and (b) STB and
term elective cesarean (TCS) delivery, respectively. To investigate
if the SPB-associated RNA that could be detected before SPB, we
analyzed maternal plasma samples collected during the presenta-
tion of preterm labor from women eventually giving SPB.
Recruitment of participants
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethics approval from the Joint
Chinese University of Hong Kong-New Territories East Cluster
Clinical Research Ethics Committee and written informed consent
from each participant were obtained. Pregnant women who were
attending the Department of Obstetrics and Gynaecology, Prince
of Wales Hospital, Hong Kong, and who were presenting with
preterm (before 34 weeks) labor (Group I), undergoing spontane-
ous term (on or after 37 weeks) labor (Group II), undergoing
elective term ($37 weeks) cesarean delivery (Group III), or having
no sign of labor before term (,34 weeks) (Group IV) were
recruited for this study. Gestational age was established based on
menstrual date confirmed by sonographic examination prior to 20
weeks gestation.
For each participant, a maternal blood sample was obtained
immediately upon recruitment, while the placenta was obtained
immediately upon delivery. Pregnancy outcomes, including the
mode of delivery and maturity were followed up. Indicated
preterm births, threatened preterm labor (term birth), multiple
pregnancies, pregnancies complicated by preeclampsia, intrauter-
ine growth restriction, fetal chromosomal and structural abnor-
malities were excluded from this study. Characteristics of the
participants in this study are shown in Tables 1 and 2.
Table 1. Characteristics of participants in the analysis of placental tissues.
Spontaneous preterm
births (SPB)
Spontaneous term
births (STB)
Term elective cesarean
deliveries (TCS) P-value
a
Number of participants (n) 1 01 01 0-
Maternal age in years (median, IQR) 32 (29–33) 31 (27–32) 30 (25–35) 0.703
Nulliparous (n, %) 6 (60%) 4 (40%) 4 (40%) 0.585
Weeks at delivery (median, IQR) 31.2 (27.0–32.6) 39.1 (38.4–40.0) 38.5 (38.4–38.6) ,0.001
b
Birthweight in grams (median, IQR) 1468 (1135–1595) 3120 (2990–3595) 3203 (3010–3730) ,0.001
b
Rupture of membrane .24 h before delivery (n, %) 4 (40%) 2 (20%) 0 (0%) 0.082
Antepartum hemorrhage (n, %) 2 (10%) 1 (10%) 0 (0%) 0.329
aKruskal-Wallis test for continuous variables. Chi-square test for nominal variables.
bStudent-Newman-Keuls test, p,0.05: SPB,STB, SPB,TCS.
doi:10.1371/journal.pone.0034328.t001
Table 2. Characteristics of participants in the analysis of maternal plasma samples.
SPB Term birth P-value
a
Number of participants (n) 1 02 7-
Maternal age in years (median, IQR) 32 (28–33) 32 (27–34) 0.707
Nulliparous (n, %) 6 (60%) 16 (59%) 1.000
Weeks at blood-taking (median, IQR) 30.9 (27.0–32.1) 31.0 (27.8–32.3) 0.891
Weeks at delivery (median, IQR) 30.9 (27.0–32.1) 39.1 (38.3–40.3) ,0.001
Birthweight (median, IQR) 1468(1135–1580) 3240(2976–3392) ,0.001
Rupture of membrane .24 h before delivery (n, %) 4 (40%) 3 (11%) 1.000
aMann-Whitney rank sum test for continuous variables. Fisher exact test for nominal variables.
SPB, spontaneous preterm birth.
doi:10.1371/journal.pone.0034328.t002
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For each case in Groups I, II and III, a piece of placental tissue
(about 0.1 cm
3) was biopsied immediately after delivery, rinsed in
phosphate buffered saline and stabilize in RNA later (Ambion), as
previously described [23]. Care was taken to minimize the
contamination of any maternal decidual tissue, the fetal mem-
branes, and blood clots in the biopsied placental tissue. For each
participant in Group I, a maternal peripheral blood sample
(12 mL) was collected into tubes containing EDTA during
presentation of preterm labor (,34 weeks), before the adminis-
tration of steroids or tocolytics, if any. For each participant in
Group IV, the maternal peripheral blood sample (12 mL) was
collected during the antenatal visit at ,34 weeks.
We stored the unprocessed blood samples at 4uC upon
collection and harvested plasma from the blood samples within
6 h [25]. Plasma was harvested from EDTA-blood by a reported
double-centrifugation protocol [26]. To improve the yield of
RNA, the processed plasma (1.6 mL) was then mixed with Trizol
LS reagent (Invitrogen) (4.8 mL), according to a recently reported
protocol [27]. All processed placental tissue and plasma samples
were stored at 280uC until RNA extraction. DNase I (Invitrogen)
treatment was performed to remove genomic DNA contamina-
tion. The quantity and quality of the RNA preparations from
placental tissue were assessed by spectrophotometer and Bioana-
lyzer (Agilent). The details are described in File S1.
Gene expression microarray analysis
The relative expression levels of essentially all human genes
were systematically profiled using the GeneChip Human Genome
U133 Plus 2.0 Array (Affymetrix). Placental tissue collected from
Groups I and II was subjected to RNA extraction and expression
profiling on microarray. The microarray data were then analyzed
by the GeneSpring GX software version 10 (Agilent). The details
are described in File S1.
Reverse-transcriptase quantitative polymerase chain
reaction (RT-qPCR)
The concentrations of mRNA transcripts coding for interleukin 1
receptor-like 1 (IL1RL1), vascular endothelial growth factor A (VEGFA),
insulin-like growth factor 2 (IGF2), glutathione peroxidase 3 (GPX3), nidogen
1 (NID1), actin, gamma 2, smooth muscle, enteric (ACTG2), transgelin
(TAGLN), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)i n
placental tissues and maternal plasma were quantified by RT-
qPCR. To minimize the effect of any contaminating genomic
DNA in the RNA preparations, the RT-qPCR assay for all mRNA
targets, except for ACTG2, were designed to be intron-spanning.
However, due to certain constrains of the mRNA sequence, the
RT-qPCR assay for ACTG2 mRNA did not span any intron.
Details of each mRNA target, the sequence and exon locations of
each primer and probes, reaction conditions and thermal profiles
are available in File S1, Tables S1 and S2.
The amplification of mRNA target was monitored and analyzed
by an ABI Prism 7900 Sequence Detection System (Applied
Biosystems) and Sequence Detection Software version 2.1 (Applied
Biosystems). For each assay, a calibration was prepared by
amplifying serial dilutions of HPLC-purified synthetic DNA
oligonucleotides (Sigma-Proligo) representing the targeted ampli-
con at known concentrations. The PCR efficiency, slope, y
intercept, correlation coefficient, dynamic range, limit of detection
(LOD) and Cq variation at LOD are tabulated in Table S3,
according to the guidelines on the Minimum Information for
Publication of Quantitative Real-Time PCR Experiments (MIQE)
[28]. Absolute concentrations of mRNA targets were calculated as
the number of copies per ng of total RNA in placenta, or as the
number of copies per milliliter of plasma. Concentrations of
mRNA targets in a sample were analyzed relative to the GAPDH
mRNA in the sample unless otherwise stated.
Statistical analysis
Statistical analyses were performed with SigmaStat 3.5 software
(Systat Software) using non-parametric tests unless otherwise
stated.
Results
Genome-wide gene expression profiling of the SPB
placentas
To test the hypothesis that SPB involves aberrant gene
expression in the placenta, we performed microarray analysis on
five placental tissue samples collected from SPB (Group I, SPB
placentas, delivered at 24.4 weeks–33.0 weeks) and compared with
another five placental tissue samples from STB (Group II, STB
placentas, delivered at 38.4 weeks–40.0 weeks). Each sample was
interrogated by 54675 probesets, representing the transcripts of
essentially all human genes. Over 47000 transcripts and their
variants, including those transcribed from more than 38500 well
characterized genes and UniGenes, were interrogated by these
microarray probes. To reduce the technical variations in the
experimental procedures in handling different samples, the
microarray data were normalized using the Robust Multiarray
Average (RMA) method [29]. We identified 1549 probe signals, or
gene expression levels, that were significantly changed between the
preterm and STB placentas (Mann-Whitney Rank Sum Test,
adjusted for multiple testing by the Benjamini and Hochberg
method [30], adjusted p,0.05). The full dataset of this microarray
experiment has been deposited at the Gene Expression Omnibus
of the National Centre of Biotechnology Information (http://ncbi.
nlm.nih.gov/GEO, accession number GSE18850). The quality
control data for the microarray experiment are shown in Table S4.
To monitor the technical variation associated with labeling and
hybridization in the microarray experiment, identical amounts of
artificial RNA controls were spiked to each RNA sample before
the labeling step. None of these spiked artificial RNA controls
displayed more than 2.9-fold differences between the term and
SPB placentas. Thus, we focused our analysis on probe signals
with .2.9-fold difference, which might be attributed to the
biological variation, rather than technical variation, between the
term and SPB placentas. The microarray data showed that 426
probe signals were changed (240 were increased and 186 were
decreased) by .2.9-fold in the preterm (SPB) placentas, compared
with the term (STB) placentas. The lists of the up-regulated genes
(Tables 3 and S5) and down-regulated genes (Tables 4 and S6) in
the SPB placentas are tabulated in the descending order of the
fold-change values.
Over-representation of functions among the lists of
aberrantly expressed genes in the SPB placentas
To test if any gene functions were over-represented, or
enriched, among the lists of up- or down-regulated genes in the
SPB placentas, we performed the gene ontology (GO) analysis.
First, each gene was mapped to its GO terms, which described the
gene functions by a set of controlled vocabulary constructed by the
Gene Ontology Consortium (AmiGO version 1.7, release 15 Jan
2011) [31,32]. Second, for each GO term, its fold of enrichment
was calculated as the ratio between its frequency in a list and its
frequency in a background comprising all genes interrogated by
the microarray (File S1). To test if the over-representation was
Preterm Birth-Associated RNA in Maternal Plasma
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experiment (Mann-Whitney test, adjusted by the Benjamini and Hochberg method, adjusted p,0.05).
Probeset ID
GenBank accession
number Gene symbol
a Gene name
a
Fold-change
up-regulated
b
234066_at
c AL117622 IL1RL1 interleukin 1 receptor-like 1 15.5
212092_at
c BE858180 PEG10 paternally expressed 10 12.2
207526_s_at
c NM_003856 IL1RL1 interleukin 1 receptor-like 1 12.0
211948_x_at BG261071 PRRC2C proline-rich coiled-coil 2C 11.7
242870_at BE551073 RIMKLB ribosomal modification protein rimK-like family member B 11.4
204864_s_at NM_002184 IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 10.6
211000_s_at AB015706 IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 10.1
208003_s_at NM_006599 NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 9.89
214055_x_at AW238632 PRRC2C proline-rich coiled-coil 2C 9.39
242809_at
c AI188516 IL1RL1 interleukin 1 receptor-like 1 9.38
244774_at
c R81072 PHACTR2 phosphatase and actin regulator 2 8.67
215342_s_at AB019490 RABGAP1L RAB GTPase activating protein 1-like 8.56
208719_s_at U59321 DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 8.50
233011_at AU155094 ANXA1 annexin A1 7.74
216493_s_at AL023775 IGF2BP3 insulin-like growth factor 2 mRNA binding protein 3 7.05
…… … … …
[Continues on Table S5
b.]
aThe RNA transcript interrogated by each probeset is shown as the gene symbol and name approved by the HUGO Gene Nomenclature Committee at the European
Bioinformatics Institute (http://www.genenames.org). Certain probesets interrogating the same gene may be listed as different GenBank accession numbers. This may
reflect the different isoforms being interrogated. Other details on the probesets are freely accessible at http://www.netaffx.com.
bOnly 15 transcripts with the greatest fold-change values are shown. The remaining 225 transcripts are shown in Table S5.
cUp-regulated transcripts with higher expression levels than the PLAC4 mRNA in the placenta, according to the microarray data.
SPB, spontaneous preterm birth; STB, spontaneous term birth.
doi:10.1371/journal.pone.0034328.t003
Table 4. RNA transcripts that were down-regulated in the SPB placentas, relative to the STB placentas, according to the microarray
experiment (Mann-Whitney test, adjusted by the Benjamini and Hochberg method, adjusted p,0.05).
Probeset ID
GenBank accession
number Gene symbol
a Gene name
a
Fold-change
down-regulated
b
228697_at AW731710 HINT3 histidine triad nucleotide binding protein 3 12.9
1558406_a_at AK000786 EXPH5 exophilin 5 8.02
216766_at AK025152 PRKCE protein kinase C, epsilon 7.39
218002_s_at NM_004887 CXCL14 chemokine (C-X-C motif) ligand 14 6.88
215191_at AW836210 KDM2A lysine (K)-specific demethylase 2A 6.63
1557512_at BM664532 CLIP1 CAP-GLY domain containing linker protein 1 5.90
213939_s_at AI871641 RUFY3 RUN and FYVE domain containing 3 5.65
215599_at X83300 — transcribed locus 5.61
233727_at AL157472 — transcribed locus 5.60
205594_at NM_014897 ZNF652 zinc finger protein 652 5.58
210701_at D85939 CFDP1 craniofacial development protein 1 5.38
216813_at AL512728 — transcribed locus 5.34
1557293_at CA418406 — transcribed locus 5.33
231644_at AW016812 — transcribed locus 5.24
1561180_at AK021807 LRP11 low density lipoprotein receptor-associated protein 11 5.04
…… …… …
[Continues on Table S6
b.]
aIf a probeset interrogates a RNA transcript with no gene symbol (‘‘—’’) approved by the HUGO Gene Nomenclature Committee at the European Bioinformatics Institute
(http://www.genenames.org), it is shown as a ‘‘transcribed locus’’. Other details on the probesets are freely accessible at http://www.netaffx.com.
bOnly 15 transcripts with the greatest fold-change values are shown. The remaining 171 transcripts are shown in Table S6.
SPB, spontaneous preterm birth; STB, spontaneous term birth.
doi:10.1371/journal.pone.0034328.t004
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performed, using the tools in the website of the Database for
Annotation, Visualization, and Integrated Discovery (DAVID)
[33] [34]. An error rate of 5% was applied to control the family-
wide false discovery rate (FDR). The gene ontology terms enriched
in the lists of up- (Table 5 and S7) and down-regulated genes
(Table 6 and S8) in the SPB placentas are tabulated.
Systematic identification of SPB-associated RNA
transcripts in maternal plasma
The data from our previous study suggest that placental
expressed transcripts can be detected in maternal plasma provided
that the expression level exceeds a threshold placental microarray
signal [23]. The PLAC4 mRNA was shown to be readily detectable
in maternal plasma [35]. Among other placental mRNA that
could be detected in maternal plasma, the PLAC4 mRNA was
expressed at a relatively low level in placental tissue and observed
to yield a relatively low placental microarray signal [23]. Thus, in
this study, we looked for transcript with higher expression levels
than the PLAC4 mRNA transcript in the placenta, because this
indicated the possibility of detecting such transcripts in maternal
plasma. In our current microarray data, the median microarray
signal of the PLAC4 mRNA in the STB placentas was 408 intensity
units. We have identified 2230 microarray signals in the SPB
placentas that were higher than this threshold, and referred them
as ‘‘highly expressed’’ RNA transcripts (Figure 1, Table S9).
To systematically identify SPB-associated RNA transcripts in
maternal plasma, we sought for transcripts that were both highly
expressed in the SPB placentas and aberrantly expressed in the
SPB placentas, compared with the STB placentas. Among these
2230 microarray signals representing the highly expressed
placental RNA transcripts, 46 microarray signals (denoted in
Tables 3, S5 and S6) were also found to be aberrantly expressed in
the SPB placentas, compared with the STB placentas, and
represented 36 placental RNA transcripts (Figure 1). Since this
panel represents SPB-associated RNA transcripts that could
potentially be detected in maternal plasma samples, we selected
them for further investigation.
Comparison of microarray data and RT-qPCR data
To assess if the fold-change values from this microarray dataset
on a small sample size was reflective of the quantitative differences
of expression levels in a larger sample size, we performed RT-
qPCR on selected mRNA transcripts. Since most of the SPB-
associated RNA transcripts that could potentially be detected in
maternal plasma samples, as identified by the above method, were
up-regulated, rather than down-regulated, in the SPB placentas,
we focused on the up-regulated transcripts for further quantitative
studies by RT-qPCR.
We selected 7 mRNA transcripts, namely those encoding
IL1RL1, VEGFA, IGF2, ACTG2, GPX3, NID1, and TAGLN for RT-
qPCR analysis in the RNA samples extracted from 10 placental
tissues each collected from SPB (delivered at 24.4 weeks–33.1
weeks; Group I) and STB (delivered at 37.3 weeks–41.4 weeks;
Group II) (Table 1). Among 10 placentas in each group, 5 of them
were collected from a different set of women than those used in the
microarray experiment. The 7 transcripts were selected because
they covered a wide range of fold-change values in the microarray
data (range, 2.90-fold to 15.5-fold). Moreover, all 7 transcripts,
except the NID1 mRNA, were identified as the SPB-associated
placental RNA that could potentially be detected in maternal
plasma (Figure 1).
As a control for the RNA extraction and equal RNA loading,
we quantified the concentrations of GAPDH mRNA transcript in
each group of the placental tissue RNA samples by RT-qPCR. No
significant difference was observed in the concentrations of
GAPDH mRNA between the two groups (Mann-Whitney rank
sum test, p=0.241). Subsequently, we compared the concentra-
tions of the 7 selected transcripts, normalized to the concentrations
of GAPDH mRNA, in this set of placental tissue RNA samples
between Groups I and II.
The RT-qPCR data showed that the medians of normalized
concentrations of IL1RL1, VEGFA, IGF2, ACTG2, GPX3, NID1
and TAGLN were 8.96-fold (Mann-Whitney rank sum test,
p=0.014), 3.27-fold (p=0.006), 1.55-fold (p=0.076), 3.70-fold
(p=0.009), 2.31-fold (p=0.002), 2.14-fold (p=0.017) and 2.32-
fold (p=0.021) higher, respectively, in the placentas collected from
SPB, than those collected from STB. All 7 mRNA transcripts,
except IGF2 mRNA, were significantly up-regulated in the SPB
placenta relative to the STB placentas. For the 7 selected
transcripts, their fold-change values according to the RT-qPCR
data ranged from 2.32 to 8.96, which were comparable to those
according to the microarray data (range 2.91 to 15.5, Figure S1).
This microarray dataset on a small sample size was essentially
concordant with the RT-qPCR data on a larger sample size.
Further characterization of aberrantly expressed RNA in
the SPB placentas
Genes that were up- or down-regulated in the SPB placenta as
identified above may be associated specifically to the pathogenesis
of SPB (preterm-associated), or to the normal physiology of a labor
process (labor-associated), or a combination of both. To further
characterize whether the 7 selected mRNA transcripts were
preterm-associated and/or labor-associated, we quantified their
mRNA expression levels in an additional group of placenta,
namely those collected from elective TCS (delivered at 38.0–39.6
weeks; Group III), before the pregnant women underwent
spontaneous labor, by RT-qPCR. The characteristics of partici-
pants in Group III are comparable to those of Groups I (SPB) and
II (STB), except the gestational weeks at delivery, birthweights,
and modes of delivery (Table 1). Since no systematic change was
observed in the concentrations of GAPDH mRNA in the placentas
from Groups I, II and III, we normalized the concentrations of the
selected mRNA transcripts with the concentrations of GAPDH
mRNA, and compare the data from the SPB, STB and TCS
placentas.
To detect if there was any difference in the normalized mRNA
concentrations among the three groups, the Kruskal-Wallis test
was performed. Our data have shown that the normalized
concentrations of all 7 selected mRNA transcripts, except the
IGF2 mRNA, were different among these three groups. To isolate
any pairwise comparison with different normalized mRNA
concentrations, the Student-Newman-Keuls test was performed.
The normalized concentrations of all seven mRNA transcripts,
except IGF2 mRNA, were higher in the SPB placentas than the
STB placentas (p,0.05, Student-Newman-Keuls; Figure 2). No
difference was observed in the normalized concentrations of the
IL1RL1, VEGFA, NID1 and TAGLN mRNA transcripts between
the STB placentas and TCS placentas (p.0.05, Student-New-
man-Keuls; Figure 2A, B, F, and G). Only the normalized
concentrations of the ACTG2 and GPX3 mRNA transcripts were
higher in STB placentas, compared with the TCS placentas
(p,0.05, Student-Newman-Keuls; Figure 2D, and E). Our data
suggested that the IL1RL1, VEGFA, NID1 and TAGLN mRNA
transcripts are likely to be involved only in the pathogenesis of SPB
(preterm-associated), but not the normal physiology of term labor
(labor-associated).
Preterm Birth-Associated RNA in Maternal Plasma
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plasma
Prompted by the results that aberrantly expressed RNA
transcripts do exist in the SPB placentas, we further hypothesize
that these RNA transcripts can be detected in maternal plasma
before the occurrence of SPB. We obtained maternal plasma
samples during preterm labor from women who eventually
resulted in SPB (Group I) and during the same gestational weeks
of blood-sampling from women with no preterm labor and who
eventually resulted in term birth (Group IV).
We quantified the concentrations of IL1RL1 mRNA, which
showed the greatest fold-change in the SPB placentas compared
with the STB placentas, in these maternal plasma samples using
RT-qPCR.The LODand the mean 6 standard deviation of Cq for
twenty technical replicates at LOD of our RT-qPCR assay for
IL1RL1 mRNA were 20 copies/mL plasma and 38.160.687 cycles,
respectively. IL1RL1 mRNA was considered to be detected only if
the RT-qPCR signal was higher than the LOD, which was
determined as the lowest concentrationat which 95% of the positive
samplesaredetected, incompliance with theMIQEguidelines[28].
Our data have shown that IL1RL1 mRNA was indeed
detectable in 6 out of 10 (60%) predelivery maternal plasma
samples collected during preterm labor (blood collected at a
median of 30.9 gestational weeks; IQR, 27.0 weeks–32.1 weeks)
from women who eventually gave SPB (delivered at #33.1
gestational weeks), as we have hypothesized.
To test if the existence of IL1RL1 mRNA in maternal plasma is
specific to symptomatic women eventually resulting SPB, we
collected gestational age-matched maternal plasma samples from
27 pregnant women with no labor and eventually resulted in term
birth for comparison (blood collected at a median of 31.0 weeks;
IQR, 27.8 weeks–32.3 weeks). The maternal and pregnancy
characteristics of these 27 gestational age-matched pregnancies
eventually resulted in term birth (delivered at ,41.1 weeks) are
comparable to the 10 women eventually resulted in SPB, except
the gestational weeks at delivery and birthweights (Table 2).
Our data showed that IL1RL1 mRNA was detected in only one
of these 27 (3.7%) plasma samples of gestation in women with no
labor eventually resulted in term birth. The detection rate of
IL1RL1 mRNA in predelivery maternal plasma samples was over
16 times higher in women with preterm labor and eventually
resulted in SPB than those with no preterm labor and eventually
resulted in term birth (Fisher exact test, p=0.00056; Table 7). As a
positive control for RNA extraction from each maternal plasma
sample, we quantified the GAPDH mRNA and observed no
difference in its plasma concentrations between the groups
eventually resulted in SPB and term birth.
Discussion
In this study, we have profiled the RNA expression levels of
essentially all human genes in the SPB placenta, and observed that
426 microarray probe signals were changed in the SPB placentas,
compared with the STB placentas (240 increased (Tables 3 and
S5) and 186 decreased (Tables 4 and S6); Mann-Whitney test,
adjusted for multiple testing by the Benjamini and Hochberg
method, adjusted p,0.05). To the best of our knowledge, this is
the first report that compared the genome-wide gene expression
profiles of between the SPB and STB placentas. Notably, this
dataset has also facilitated the first systematic identification of a
panel of 36 SPB-associated RNA transcripts, which are potentially
detectable in maternal plasma (Figure 1).
None of the previous transcriptomic studies compared the
genome-wide profiles between the SPB and STB placentas,
although one recent study compared the profiles between the
SPB and the TCS placentas [19], which were collected from
spontaneous delivery and elective cesarean delivery, respectively.
Hence, the subsequent gene expression data might be confounded
by the different modes of delivery. In contrast, our study compared
the placental microarray data between SPB and STB, both of
which had undergone spontaneous delivery. Thus, the differential
gene expression patterns identified in our dataset are not
confounded by the mode of delivery. Among the 426 SPB-
associated genes identified in our study comparing SPB and STB
placentas, only 5 were identified in the study comparing SPB and
TCS placentas [19].
Figure 1. Systematic identification of SPB-associated placental transcripts in maternal plasma. Shown in the Venn diagram are the
number of microarray probesets representing transcripts which are highly expressed (pale yellow) and aberrantly expressed (red) in the SPB
placentas. Transcripts fulfilling both criteria (orange) are potentially detectable in maternal plasma samples obtained from women eventually
resulting in SPB. These probesets represent 36 transcripts and are shown in the box, along with the fold-change up-regulated (up arrow) or down-
regulated (down arrow) in the SPB placentas, compared with the STB placentas. For transcript represented by more than one probesets, its average
fold-change is shown. Transcripts with no official gene symbols are shown in their GenBank accession numbers. Transcripts chosen for RT-qPCR are
shown in bold. SPB, spontaneous preterm birth. STB, spontaneous term birth.
doi:10.1371/journal.pone.0034328.g001
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34328Besides the mode of delivery, previous microarray studies
concerning SPB were often confounded by the underlying
obstetric complications indicating for a preterm elective cesarean
delivery. For instance, a recent microarray study compared the
gene expression data between SPB and indicated preterm births
by cesarean section at 32–34 weeks of gestation (indications: fetal
growth restriction, placental abruption, placenta previa, spinal
fusion) [20]. In contrast, we have excluded indicated preterm
births from our study. Thus, the differential gene expression
patterns identified in our dataset are neither confounded by the
underlying obstetric complications in indicated preterm births.
To verify if our microarray experiment and our data-ming
methods were performed properly, we repeated the measurement
of gene expression levels using another platform, namely RT-
qPCR, in a different set of samples. Seven transcripts with various
fold-change values (range, 2.90-fold to 15.5-fold) on the micro-
array datasets were selected for further investigation by RT-qPCR
in 20 pregnancies. The RT-qPCR data from 6 of 7 (86%)
transcripts were concordant with the microarray data (Figure 2A,
B, D–G; SPB vs. STB, p,0.05). The only discordant data on the
IGF2 mRNA (Figure 2C; SPB vs. STB, p$0.05) may arise due to
its multiple transcript variants, which require multiple variant-
specific RT-qPCR assays for more accurate quantification.
Nevertheless, this suggested that our microarray data on a small
sample size is representative of the quantitative difference in RT-
qPCR data in a larger cohort.
Furthermore, we have shown that the differential mRNA
expression of gene as small as 2.9-fold on the microarray (TAGLN)
could be replicated on the RT-qPCR platform in the larger cohort
(Figure 2G; SPB vs. STB, p,0.05). Thus, we reason that the lists
of up- and down-regulated genes (threshold, .2.9-fold on
microarray; Tables 3, 4, S5, S6), identified by our microarray
experiment and our data-mining methods, represent genes that are
differentially expressed in the clinical samples.
Based on this SPB placental microarray dataset that is
representative, not confounded by mode of delivery nor other
obstetric complications, we further investigated into the mechanistic
aspects of SPB in humans. Among the 7 transcripts tested by RT-
qPCR, 4 transcripts (the IL1RL1, VEGFA, NID1 and TAGLN
mRNA) showed difference in concentrations only between the SPB
placentas and the STB placentas, but no difference between the
STB placentas and the TCS placentas (Figure 2A, B, F, and G; SPB
vs. STB, p,0.05; STB vs. TCS, p$0.05). This implies these RNA
transcripts are involved specifically in the pathological physiology of
SPB, but not in the normal physiology of labor process.
In fact, although the 2 other tested transcripts (the ACTG2 and
GPX3 mRNA) showed higher concentrations in the STB placentas
than the TCS placentas (Figure 2D, and E; STB vs. TCS, p,0.05),
their concentrations were in turn higher in the SPB placentas than
the STB placentas (Figure 2D, and E; SPB vs. STB, p,0.05). This
implies that, while the concentrations of ACTG2 and GPX3 mRNA
are changed in the normal physiology of labor process, their
concentrations are further changed in the pathological physiology
of SPB. Taken together, 6 of the 7 (86%) RNA transcripts
identified by the above approach are predominantly associated
with the pathological physiology of SPB.
To gain further insights into the known functions of genes up-
regulated in the SPB placentas, compared with the STB placentas,
we performed the GO analysis the list of genes in Tables 3 and S5.
Not surprisingly, we observed an over-representation of gene
functions involving acute inflammatory response (Table S7). This
is in line with the literature that intrauterine infection or
inflammation is implicated in the pathological processes of SPB
[36]. Interestingly, we also observed an over-representation of
gene functions involving RNA stabilization (Table 5). Recently, a
compound with ribonuclease inhibitor activity has been shown to
limit the growth of important gram-positive bacterial pathogens
and protected against S. aureus pathogenesis in an animal model of
infection [37]. We speculate that the up-regulation of genes
involved in RNA stabilization (e.g. ribonuclease inhibitor activity)
may be a response to invading pathogens in the SPB placentas.
Moreover, among the genes up-regulated in the SPB placentas,
we observed an over-representation of gene functions in extracel-
lular matrix binding (Table 5), including the thrombospondin 1
(THBS1) and the vascular endothelial growth factor A (VEGFA) mRNA.
The VEGFA protein has been found to be elevated in the decidual
cells of women with intra-amniotic infection, which is a major cause
of SPB [38]. The THBS1 protein has been found to be elevated in
the cervicovaginal fluids of women undergoing SPB,compared with
those undergoing term births [39]. The THBS1 mRNA has also
been shown to be elevated during term and preterm parturition in
the myometrium of sheep [40] and the uterus of mice [41].
Furthermore, gene functions involving with actin filament (Table 5)
were also over-represented among the genes up-regulated in the
SPB placenta, including caldesmon 1 (CALD1), which is implicated in
the stretch-dependent myometrial activation in human myometri-
um [42]. Thus, the involvement of the aberrant RNA expression of
these genes in the SPB placenta, as revealed in this study, echoes
well with their aberrant expression in the myometrium and other
tissue collected from SPB, as reported in the literature.
Interestingly, we have observed that the insulin-like growth factor 2
mRNA binding protein 3 (IGF2BP3) mRNA and the IGF1R mRNA
were up-regulated by 7.05- and 3.39-fold, respectively, in the SPB
placentas, compared with the STB placentas (Tables 3 and S5).
Recently, a linkage, haplotype sharing, and association analysis
has provided the evidence for IGF1R as a SPB predisposition gene
Figure 2. Box plots of the concentrations of RNA transcripts in the placentas as determined by RT-qPCR. Seven transcripts (A–F) with
different fold-change values on the microarray dataset were selected for further investigation by RT-qPCR in the placentas collected from SPB, STB
and TCS. The line inside each box denotes the median. Limits of the box denote the 25
th and 75
th percentiles. Whiskers denote the 10
th and 90
th
percentiles. Filled circles denote the 5
th and 95
th percentiles. Asterisks denote the any pairwise comparisons that are significantly different (p,0.05,
the Student-Newman-Keuls test). SPB, spontaneous preterm birth. STB, spontaneous term birth. TCS, elective term cesarean delivery.
doi:10.1371/journal.pone.0034328.g002
Table 7. Detection of IL1RL1 mRNA in gestational age-
matched maternal plasma samples.
IL1RL1 mRNA
Number of women
resulted in SPB
a
Number of women
resulted in term birth
b
Positive ($20 copies/mL
maternal plasma)
61
Negative (,20 copies/mL
maternal plasma)
42 6
Total 10 27
aBlood sample collected from women at 30.9 weeks (median; IQR, 27.0–32.1
weeks) of gestation, during the presentation of preterm labor (Table 2).
bBlood sample collected from women at 31.0 weeks (median; IQR, 27.8–32.3
weeks) of gestation (Table 2).
SPB, spontaneous preterm birth.
doi:10.1371/journal.pone.0034328.t007
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34328[14]. Previously, a 11-kDa proteolytic fragment of the insulin-like
growth factor binding protein 1 (IGFBP1) protein was reported to be up-
regulated in the amniotic fluid and maternal serum of pregnant
women with intra-amniotic infection [17]. Taken altogether, IGF
and its associated molecues may play some roles in the
pathogenesis of SPB. In our GO analysis, among the up-regulated
genes in the SPB placentas, the frequency of IGF2BP3 and other
genes involved in posttranscriptional regulation were 4.52-fold
overrepresented (Table S7). Moreover, among the up-regulated
genes, the frequency of IGF1R and 9 other genes involved in anti-
apoptosis were 4.63-fold overrepresented (Table S7). Thus, we
speculate that posttranscriptional regulation and anti-apoptosis
may also be involved in the pathogenesis of SPB.
Most importantly, we have systematically identified a panel of
36 RNA transcripts which are aberrantly expressed in the SPB
placentas, and are expressed at a high enough level to be
detectable in maternal plasma (Figure 1). We have demonstrated
that the IL1RL1 mRNA, as identified above, was detected in 60%
of predelivery maternal plasma samples collected during preterm
labor (24–33 weeks 32.9 weeks) from women eventually resulted in
SPB. In contrast, the IL1RL1 mRNA was detected in only 3.7% of
maternal plasma samples collected during the same gestational
period in women not in labor. The data suggest that the existence
of IL1RL1 mRNA in the predelivery maternal plasma is associated
with preterm labor and/or SPB. This promising data warrant
further investigation. First, how early does the IL1RL1 mRNA
appear in maternal blood before SPB? Second, will the IL1RL1
mRNA in maternal plasma improve the sensitivity of the existing
methods, namely fetal fibronectin from cervicovaginal secretion
and transvaginal cervical length [43,44], in predicting SPB? Third,
is IL1RL1 mRNA in maternal plasma involved in all clinical sub-
groups of SPB (e.g. with or without preterm pre-labor rupture of
membranes, cervical incompetence, antepartum hemorrhage)?
As the other 35 SPB-associated RNA transcripts (Figure 1) are
also identified as aberrantly expressed in the SPB placentas by our
microarray experiment, further investigation, which may be
achieved through maternal plasma detection, into their roles in
SPB are warranted. For example, it would be interesting to
correlate the maternal plasma concentrations of these SPB-
associated RNA with any clinical outcomes/parameters of the
pregnancies presented with preterm labor. Besides, to further
study the molecular functions of the above genes in pregnancy and
SPB, one may overexpress or knockout the concerned genes in
animal models. Nevertheless, the work presented here has
provided the essential groundwork for such further attempts to
study SPB. Before this work, the difference between the genome-
wide expression profiles of the SPB and STB placentas had not
been compared, and systematic identification of markers for SPB
in maternal blood had not been possible. These issues were
addressed at least partially by the work presented here.
Furthermore, we have illustrated with our data that SPB-
associated RNA in maternal plasma could be detected before SPB
eventually occurred (Table 7). In contrast, markers derived from
the myometrium and fetal membranes are not readily measurable
for evaluation during preterm labor, or until SPB eventually
occurs. The analysis of SPB-associated placental RNA transcripts
in predelivery maternal plasma samples facilitates the fairer
comparison of pregnancies presenting with preterm labor and
gestational age-matched pregnancies with no preterm labor. We
reason that this fairer comparison with gestational age-matched
controls will in turn lead to discovery of better and more powerful
markers in predicting SPB.
By providing this panel of 36 SPB-associated RNA markers in
maternal circulation, we hope to alleviate the current lack of
markers for SPB in predelivery clinical samples that can be easily
compared with gestational age-matched normal controls. This
strategy for the systematic identification of novel blood-based
markers may also be generalized to other pregnancy-associated
complications, which involve aberrant gene expression in the
placenta. In summary, the current study has not only brought
insights into the molecular biology of the placenta delivered by
SPB, but also provided a list of SPB-associated RNA markers in
maternal plasma for studying and monitoring SPB.
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